Pomerantz Law Firm Investigates Potential Securities Fraud at Galectin Therapeutics for Investors

Investor Alert: Pomerantz Investigation into Galectin Therapeutics

Pomerantz LLP has announced an investigation regarding claims made by shareholders of Galectin Therapeutics Inc. (NASDAQ: GALT). The inquiry is focused on whether the company, along with some of its senior executives and board members, has been involved in securities fraud or engaged in other unlawful business practices. The firm encourages investors who believe they may have been affected to reach out directly to Danielle Peyton at Pomerantz.

The catalyst for this investigation stems from an announcement made by Galectin on December 19, 2025, whereby they relayed a response from the U.S. Food and Drug Administration (FDA) concerning their development program for belapectin, a galectin-3 inhibitor. The FDA opted for a written communication regarding Galectin’s request for a Type C meeting, converting the original request, which sought either an in-person or telephonic dialogue, into written feedback. Despite this communication, specific key components of the clinical trial design remain ambiguous, and the firm plans to pursue further dialogue with the FDA to resolve these uncertainties.

Following the release of this information, Galectin experienced a significant decline in stock price, plummeting by $1.78 (approximately 28.9%) to a closing price of $4.38 per share on the same day. This drastic drop has raised concerns among investors who are now questioning whether proper disclosures and actions were taken by the company leading up to this announcement.

Pomerantz, with an illustrious history dating back over 85 years, is recognized as a leader in handling corporate, securities, and antitrust class actions. Founded by the late Abraham L. Pomerantz, the firm laid the groundwork for securities litigation, fighting for shareholder rights and challenging corporate malpractice. In the years following its inception, Pomerantz has successfully secured multi-million-dollar recoveries for those affected by various forms of corporate misconduct.

If you are a shareholder of Galectin Therapeutics and wish to learn more about the potential legal actions being considered, it is advisable to contact Pomerantz LLP as soon as possible. The investigation aims to ensure that investors' interests are protected and to explore avenues for remedy should any wrongdoing be found.

Pomerantz's legal representatives are prepared to assist investors in navigating any claims they may need to pursue against the company, based on the current developments. For more details, investors can visit www.pomlaw.com or get in touch directly with Danielle Peyton via her provided contact information.

Contact Information:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980

Note: Prior results do not guarantee similar outcomes. Full transparency and communication are paramount as this investigation unfolds, shedding light on the practices of Galectin Therapeutics and their implications for current and future investors.